Co-Authors
This is a "connection" page, showing publications co-authored by Michael Thirman and Caner Saygin.
Connection Strength
0.620
-
Targeting Menin in T-lineage Acute Lymphoblastic Leukemia. Mol Cancer Ther. 2026 Aug 04; 25(8):1294-1304.
Score: 0.246
-
Socioeconomic determinants of the biology and outcomes of acute lymphoblastic leukemia in adults. Blood Adv. 2024 01 09; 8(1):164-171.
Score: 0.206
-
Outcomes of patients with relapsed/refractory acute leukaemia treated with revumenib with a focus on post-revumenib therapies. Br J Haematol. 2026 Jan; 208(1):343-347.
Score: 0.058
-
Outcomes for Patients With Myeloid Neoplasms Treated With Chemotherapy Plus Venetoclax After Prior Venetoclax Therapy. EJHaem. 2025 Jun; 6(3):e70078.
Score: 0.057
-
Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy. Leuk Lymphoma. 2024 06; 65(6):864-867.
Score: 0.052